Dr. Dasilva presents findings from a real-world case series evaluating treatment options for patients with treatment-resistant chronic pruritus, highlighting the marked efficacy of Nemolizumab. His discussion focuses on how targeted biologic therapy can offer meaningful relief for patients who have failed multiple prior treatments.
Topics Covered
- Challenges in managing chronic pruritus resistant to standard therapies
- Real-world case series data supporting nemolizumab efficacy
- Mechanisms behind targeted therapy for chronic itch
- Clinical implications for treating difficult dermatologic cases
Reference
Dasilva D, Soto-González A, Mollanazar NK, et al. Nemolizumab Demonstrates Marked Efficacy in Challenging Chronic Pruritus: A Real-world Multicenter Case Series. Journal of Clinical and Aesthetic Dermatology. 2025;18(9):40–46.
Explore Related Resources
